SCHEMBL731049

SCHEMBL731049

N#Cc1c[c]ccc1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.44
ALDH1A1 P00352 4/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
KDM4E B2RXH2 2/20 0.40
HPGD P15428 2/20 0.40
GALR3 O60755 1/20 0.40
GAA P10253 1/20 0.40
GABRG2 P18507 1/20 0.39
GABRB3 P28472 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
MAOA P21397 2/20 0.38
MAOB P27338 2/20 0.38
LRRK2 Q5S007 2/20 0.38
TDP1 Q9NUW8 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CYP19A1 P11511 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6799885 0.88 ESR2 (0.38) ESR2
SCHEMBL7465565 0.84 ESR2 (0.44) ESR2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL1207001 0.82 ESR2 (0.46) ESR2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL28633390 0.81 LRRK2 (0.41) ESR2ALDH1A1NPSR1KDM4EHPGD
SCHEMBL28334386 0.81 LRRK2 (0.41) ESR2ALDH1A1NPSR1KDM4EHPGD
SCHEMBL20774359 0.80 CLK4 (0.45) GABRG2GABRB3GABRA5GABRA3MAOB
SCHEMBL223 0.76 ESR2 (0.69) ESR2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL29662886 0.76 ESR2 (0.69) ESR2ALDH1A1CYP1A2CYP2C9CYP2C19
Water SCHEMBL3178714 0.76 ESR2 (0.69) ESR2ALDH1A1CYP1A2CYP2C9CYP2C19
SCHEMBL618853 0.76 BACE1 (0.39) ALDH1A1HPGDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102911128-A Synthetic method of valsartan SUZHOU TIANLV BIO PHARMACEUTICAL CO LTD 2013-02-06 CN claimed
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
CN-102911128-A Synthetic method of valsartan SUZHOU TIANLV BIO PHARMACEUTICAL CO LTD 2013-02-06 CN disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed
EP-1244617-A1 SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE Ortho-McNeil Pharmaceutical, Inc. (US) 2002-10-02 EP disclosed
WO-2001047875-A1 SUBSTITUTED AMINOALKYLAMIDE DERIVATIVES AS ANTAGONISTS OF FOLLICLE STIMULATING HORMONE ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2001-07-05 WO disclosed
CN-1058966-C Producing process for crystal of 2-oxyethyl-1-[2'-(1H-tetrazole-5-radical)diphenyl-4-(methyl)benzimidazole-7-hydroxy acid 1-(cyclohexyloxy) ethyl ester TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2000-11-29 CN disclosed
CN-1048486-C Benzimidazole derivatives and their preparation TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2000-01-19 CN disclosed
CN-1147515-A Producing process for crystal of 2-oxyethyl-1-[2'-(1H-tetrazole-5-radical)diphenyl-4-(methyl)benzimidazole-7-hydroxy acid 1-(cyclohexyloxy) ethyl ester TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1997-04-16 CN disclosed
CN-1061973-A Thienoimidazole derivatives and preparation method thereof and purposes TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1992-06-17 CN disclosed
CN-1055927-A Benzimidazole derivatives, their preparation and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1991-11-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 ESR2 708/4885ALDH1A1 113/4885CYP1A2 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.